BPC-157: Compound Profile

BPC-157 is one of the most-searched compounds in the research-peptide market, and one of the most over-claimed. The published evidence base is genuinely interesting — a coherent, multi-tissue preclinical signal accumulated over thirty years — but it is also almost entirely preclinical, concentrated in a single research group, and not translated through the controlled human trials that would establish either efficacy or safety in patients. This profile is an attempt to describe the molecule the way the primary literature actually describes it.

Nothing in this article is a recommendation. BPC-157 is supplied by PepMax under the product slug bpc-157 for laboratory research use only. It is not approved by FDA, EMA, MHRA, Health Canada, or any other regulator we ship to for human or veterinary therapeutic use.

At a glance

The following data sheet summarizes the molecule’s identity. Sequence and molecular formula derive from the original Sikirić characterization^[1] and independent synthesis records that have appeared in subsequent papers.

What BPC-157 is

BPC stands for Body Protection Compound: a fraction of human gastric juice described by Sikirić, Petek, Rucman, Seiwerth and colleagues at the University of Zagreb in the late 1980s and early 1990s, which appeared to protect the stomach against ethanol and NSAID-induced injury^[1]. BPC-157 is a synthetic 15-amino-acid sequence within that compound that retained the protective activity in animal models. The designation that appears most often in the literature is pentadecapeptide BPC 157; the Pliva development code PL 14736 is the same molecule under a clinical-program identifier.

Three properties anchor the molecular identity. The first is the sequence itself (GEPPPGKPADDAGLV), which is reported across the Sikirić papers and reproduced by independent synthesis groups. The second is the molecule’s reported stability in human gastric juice ex vivo — the basis for the “stable gastric pentadecapeptide” descriptor that appears in dozens of paper titles^[5]. The third is the absence of a single identified high-affinity receptor: BPC-157’s reported activity is pleiotropic and is interpreted in the literature as the convergence of several signaling pathways rather than the canonical agonism of one binding site.

Proposed mechanisms

Because no canonical receptor has been identified, the BPC-157 literature describes mechanism as a constellation of downstream signals that have been independently reproduced in multiple injury models. Four pathways are most consistently cited.

Nitric-oxide system

Across vascular and gastric models, BPC-157 has been reported to interact with the L-arginine–NO pathway: counter-regulating both excessive NO production (e.g. endotoxin-driven hypotension) and inadequate NO production (e.g. L-NAME-induced hypertension and tissue injury) in the same animals^[6]. The interpretation in the Sikirić body of work is that BPC-157 acts as a homeostatic modulator of vascular tone and endothelial function rather than as a pure agonist or antagonist.

VEGFR2 and angiogenesis

The most directly characterized signaling event in the BPC-157 literature is VEGFR2 upregulation. Hsieh and colleagues (2017) reported that BPC-157 activated VEGFR2 in cultured endothelial cells in the absence of exogenous VEGF, drove formation of capillary-like networks in Matrigel, and promoted angiogenic sprouting in the chick chorioallantoic membrane assay^[4]. Earlier work by Seiwerth and colleagues had grouped a series of vascular-effect findings under a similar interpretation: accelerated reperfusion of ischemic tissue, reduced thrombus formation in venous occlusion, and faster vessel rebound in inferior caval vein syndrome models^[6][9].

FAK–paxillin pathway in tendon

Chang and colleagues (2011) reported that BPC-157 increased tendon-fibroblast outgrowth, survival, and migration in vitro, and that those effects were associated with activation of focal adhesion kinase (FAK) and paxillin signaling^[3]. This is the most often-cited mechanistic anchor for the popular “BPC-157 helps tendon” framing. The original paper is a cell-culture study; the in vivo extrapolation has been carried by a subsequent series of rat Achilles transection and rotator-cuff models from the Sikirić group.

Brain–gut axis

A 2016 review by Sikirić and colleagues consolidates a series of CNS-related findings — effects on dopamine and serotonin systems, neuroprotection in stroke and traumatic brain injury models, and behavioral effects in models of haloperidol-induced catalepsy and amphetamine-induced disturbances — under a brain–gut-axis interpretation^[7]. This is the least mechanistically well-defined of the four pathways: it is a heading under which several distinct experimental observations have been grouped, not a single biochemical pathway with a defined receptor and downstream cascade.

Evidence map

The figure below summarizes the published BPC-157 evidence base by tissue or system. Each row reflects the highest level of evidence we have been able to identify from peer-reviewed sources, not the volume of studies. Where evidence is limited to in vitro or animal models, that is stated explicitly.

Tendon and musculoskeletal models

The tendon literature is the most developed sub-corpus and the most frequently cited outside the originating group. Chang et al. (2011) demonstrated in vitro that BPC-157 upregulates the growth-hormone receptor on tendon fibroblasts and activates the FAK–paxillin pathway, with corresponding increases in cell migration and tube-formation-like behavior^[3]. Subsequent rat studies of Achilles and quadriceps tendon transection reported faster functional recovery and improved histology in treated animals. The translation from cell culture and rat to clinically relevant human tendon healing has not been performed under controlled conditions.

Gastrointestinal models

The original BPC characterization grew from gastric-mucosal protection: ethanol-induced ulcer, restraint-stress ulcer, and NSAID-induced gastropathy in rats^[1][2]. Subsequent papers extended the framework to the duodenum, the small bowel, and the colon, with reports of attenuated injury in trinitrobenzenesulfonic-acid (TNBS) colitis and in cysteamine-induced duodenal lesions. The compound’s reported stability in human gastric juice is the basis for the “stable gastric pentadecapeptide” descriptor and the rationale for oral as well as parenteral administration in animals^[5].

Vascular and angiogenic models

Seiwerth and colleagues (2014) compiled the vascular-effect literature into a single review^[6], and Vukojevic and colleagues (2020) extended it with a venous-occlusion model that examined inferior caval vein syndrome^[9]. The recurring finding is rapid functional re-vascularization after acute vascular insult: the proposed mechanism is the VEGFR2 upregulation and pro-angiogenic activity reported independently by Hsieh and colleagues (2017)^[4].

Central and peripheral nervous system

The central-nervous-system literature is the most heterogeneous: it includes rodent haloperidol catalepsy, amphetamine-induced behavioral disturbance, MPTP and 6-OHDA models of nigrostriatal injury, ischemic stroke models, and traumatic brain injury models. The 2016 brain–gut axis review^[7] brings these under a single framework that ties peripheral protective effects to CNS readouts. As with the rest of the corpus, the data are animal-only.

Human data

The most substantive human program is the development of PL 14736, the clinical designation for BPC-157, by Pliva (now Teva) for inflammatory bowel disease in the 2000s^[10]. ClinicalTrials.gov records confirm a Phase II ulcerative colitis program. The program did not advance to Phase III, and a complete peer-reviewed efficacy publication is not available; what exists is conference reporting and registry records. There is no published Phase III data, no registration program in any major jurisdiction, and no controlled human trial of BPC-157 in tendon, vascular, or neurological indications.

Research timeline

Limitations of the evidence base

Read together, the BPC-157 literature describes a coherent pharmacological story. Read critically, it has limits that any researcher evaluating the molecule should understand explicitly.

• Single-laboratory dominance.A large fraction of the in vivo work comes from the Sikirić group at the University of Zagreb. This is a productive, peer-reviewed program — but multi-site replication is the standard by which regulatory-grade evidence is judged, and that standard has not been met.
• Mechanism by association. The four mechanisms summarized above are reported in different experimental systems, not co-measured in a single integrated study. A unified pharmacological model exists in the review literature but not yet in a single primary paper.
• No phase III, no approval. The PL 14736 ulcerative-colitis program is the closest the molecule has come to a controlled human efficacy readout. It did not advance, and the absence of a published completed Phase II efficacy paper is itself a data point.
• Pharmacokinetics in humans. Plasma half-life, oral bioavailability, tissue distribution, and metabolic fate in humans are not well characterized in the peer-reviewed literature. Dosing claims circulating in non-academic contexts are extrapolations from rodent dosing scaled by body weight, not validated human PK.
• Long-term safety. The animal record does not document overt toxicity at the doses tested, but absence of evidence at limited dose ranges and durations is not evidence of long-term safety. There is no published long-term human safety dataset.

Reconstitution & handling

BPC-157 is supplied as a lyophilized powder. Standard practice across the peptide literature is reconstitution in bacteriostatic water (0.9% benzyl alcohol) for short-term storage in solution, or in sterile water for injection when the bacteriostatic preservative is undesirable for a given research design. Once reconstituted, the peptide is stored at 2–8 °C and is generally treated as stable for a number of weeks — well-documented stability data in solution are scarce and depend on concentration, pH, and freeze–thaw history. For longer-term storage, the lyophilized powder is held at −20 °C or below, protected from light and moisture.

For background on what the analytical numbers on a peptide’s certificate of analysis actually mean — HPLC purity, mass-spectrometric identity confirmation, water content — see our companion methods articles on what ≥99% purity actually means and how we verify peptide purity.

Further reading

The bibliography below points to the primary papers and reviews referenced in this profile. Where a single number is cited multiple times in the text, it indicates the same source supporting different statements rather than independent corroboration.